United StatesHealthcare and life sciences2022 – ongoingTempus AI
SmartPath-assisted tissue preparation for molecular sequencing
Tempus reported 25% more DNA yields within its target range in a SmartPath validation trial
Problem
Pathologists estimated how much tissue to extract for sequencing. Incorrect estimates could waste tissue or require another extraction.
Approach
Tempus developed SmartPath to identify tumor regions in digitized slides and predict DNA yield. It recommended extraction areas and slide counts for pathologists. An internal laboratory trial compared assisted review with traditional review across 501 clinical colorectal cancer slides.
Results
Takeaway
The measured result concerned tissue preparation in an internal trial. It did not establish a reduction in total laboratory costs.
Categories
- Industry
- Healthcare and life sciences
- Business function
- Production and quality
- Innovation type
- Process innovation
- AI technology
- Computer visionPredictive analytics and ML
- Adoption
- Built in-house
- Evidence
- Company's own claim
Sources
Source summaries
Tempus researchers described SmartPath and an internal laboratory validation. The assisted group produced 25% more DNA yields within the specified range than the traditional-review group.
Full details are in the original sources.